Luxa to Present Phase 1/2a Clinical and Preclinical Data on RPESC-RPE-4W Therapy for Dry AMD at 2025 ARVO Annual Meeting

FORT LEE, N.J.--(BUSINESS WIRE)--Luxa Biotechnology LLC (Luxa), a clinical-stage biotechnology company developing novel adult retinal pigment epithelial stem cell (RPESC) therapies for dry age-related macular degeneration (dry AMD), today announced the company will present Phase 1/2a clinical and preclinical data on the company’s adult retinal pigment epithelial stem cell (RPESC) therapy for dry age-related macular degeneration (AMD) at the 2025 ARVO Annual Meeting taking place May 4-8, 2025 in